Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

Go back to Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
(NASDAQ: ALLR) Delayed: 1.21 --0 (-0%)
Previous Close $1.21    52 Week High
Open $1.21    52 Week Low
Day High $1.21    P/E N/A 
Day Low $1.21    EPS
Volume 18,106       

(NASDAQ: ALLR) Delayed: 1.21 --0 (-0%)
Previous Close $1.21    52 Week High
Open $1.21    52 Week Low
Day High $1.21    P/E N/A 
Day Low $1.21    EPS
Volume 18,106